GlassScriptPhysician profile
Carmine C Marchioli
NPI 1861592016
$7,149.74
in general payments reported to CMS, 2019-2025
61 companies · $561 in 2025
The $561 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,082 · 2020: $353 · 2021: $610 · 2022: $1,039 · 2023: $1,521 · 2024: $984 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.64 |
| Education | $281.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $521.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $495.35 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Incyte Corporation | $420.58 | 2019-2025 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $411.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $375.12 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $331.55 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Exelixis INC. | $312.34 | 2019-2023 | Cabometyx |
| Amgen INC. | $291.17 | 2019-2023 | Lumakras, Kyprolis |
| Eisai INC. | $274.92 | 2019-2025 | |
| Genentech USA, INC. | $250.48 | 2019-2025 | Itovebi, Tecentriq, Columvi |
| Abbvie INC. | $234.78 | 2019-2025 | |
| Janssen Biotech, INC. | $227.80 | 2019-2025 | Rybrevant, Erleada |
| Astrazeneca Pharmaceuticals LP | $207.28 | 2019-2024 | Enhertu, Calquence |
| Lilly USA, LLC | $201.16 | 2019-2023 | Jaypirca, Verzenio, Retevmo |
| Rigel Pharmaceuticals, INC. | $177.40 | 2019-2024 | Tavalisse, Rezlidhia |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmine Marchioli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.